The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and outcomes.
Between 1 May 2014 and 31 January 2023, 500 patients diagnosed with World Health Organisation (WHO) Group with confirmed pulmonary arterial hypertension were enrolled ccross the 26 participating centers of IPHNET. The most common subtypes were idiopathic pulmonary arterial hypertension (40.6%), connective tissue disease–associated pulmonary arterial hypertension (26.4%), and congenital heart disease–associated pulmonary arterial hypertension (16.4%). This collaborative national registry provides an important foundation for tracking clinical trajectories and improving risk stratification for pulmonary arterial hypertension patients in Italy.
Risk classification varied depending on the method used: European Respiratory Society(ERS)–European Society of Cardiology (ESC) guidelines: 41% low risk, 57% intermediate risk; REVEAL 2.0: 70% low risk, 19% intermediate risk, 11% high risk. Regarding treatment, 35% of patients received monotherapy, 44% dual therapy, and 20% triple therapy.
The article ends by stating that the study aims to present the clinical characteristics of the Italian pulmonary arterial hypertension patients and that this cohort of patients will be followed in the ongoing registry to provide important insight into risk stratification and mode of death.
The article is not open access so we could not have any further information.
Read more at this link on ELSEVIER Science Direct
Check out the iPHNET website here
